anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A composition containing tetramethyl pyrazine and madecassoside is provided to enhance nutrition and to promote hair growth. CONSTITUTION: A composition for promoting VEGF(vascular endothelial growth factor) generation contains tetramethyl pyrazine of chemical formula 1, madecassoside of chemical formula 2, or a mixture thereof as an active ingredient. A composition for promoting hair growth and treating hair damage contains tetramethyl pyrazine, madecassoside, or a mixture thereof as an active ingredient. The total content of the active ingredient is 0.00001-10 weight%. The tetramethyl pyrazine and madecassoside are isolated from ligusticum chunaxiong and Centella asiatica, respectively. The composition is used in the form of a semi-solid formulation or liquid phase formulation.
Group C will have their therapy discontinued acutely at baseline (week 0); i.e., these subjects will not take any tablets after the 8-week stabilization phase ends. While we recognize that this group will not be blinded to the regimen they are receiving, we feel that group C will be important to include in light of the consistent decrease in vasomotor symptoms experienced by women taking placebo. Because women taking placebo have approximately a 35% decrease in vasomotor symptoms, it will be important to compare our taper regimen to the "real life" scenario of stopping medication abruptly.
A compound Chinese medicine for treating connective tissue disease related Raynaud phenomenon, warming channel and dredging collaterals, belongs to the technical field of compound Chinese medicine preparation. The compound traditional Chinese medicine for warming channel and invigorating pulse is composed of 15-24 parts of radix astragali Preparata, 5-15 parts of cassia twig, 1-5 parts of asarum, 5-15 parts of white paeony root, 10-15 parts of radix salviae miltiorrhizae, 2-5 parts of myrrh, 1-3 parts of pseudo-ginseng, 8-15 parts of bletilla striata, 5-12 parts of white mustard seed, 10-14 parts of luffa, 5-15 parts of medicated leaven, 3-8 parts of ginger, 10-18 parts of jujube and 5-12 parts of liquorice. The disease is the symptoms of the deficiency and the excess, the deficiency of qi and yang is the root, and the stagnation of qi and blood stasis are the symptoms. The yang deficiency causes the weakness of the pulse, which is liable to cause qi stagnation and blood circulation retardation, and the obstruction of the collaterals can induce or aggravate the illness. Therefore, the invention selects the medicines for common use, has the effects of invigorating qi, warming channels, regulating blood and removing arthralgia, and is integrally combined with the medicines to strengthen superficies without retaining evil or dispelling evil without damaging the vital qi and the evil and the vital qi. Has better treatment effect on the Raynaud phenomenon related to connective tissue diseases.
<P>PROBLEM TO BE SOLVED: To provide secondary para-phenylenediamines containing a new group of N-fluoroalkyls which enables strong, beautiful, uniform coloring with various tones and are sufficiently resistant to various factors to which a fiber is vulnerable.  <P>SOLUTION: The secondary paraphenylenediamines contain a novel group of carboxy groups. Alternatively, the secondary paraphenylenediamines contain a novel group of N-fluoroalkyls. These are used for oxidation dyeing of the hair. A composition for dyeing a keratin fiber, especially a human keratin fiber such as the hair, contains at least one N-heteroaromatic secondary paraphenylenediamine in a medium suitable for dyeing. The composition is used in a method for dyeing the keratin fiber, especially the human keratin fiber such as the hair. The use of the composition and a dyeing "kit" are also provided.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
A system and method for building and/or manipulating a centralized medical image quantitative information database aid in diagnosing diseases, identifying prevalence of diseases, and analyzing market penetration data and efficacy of different drugs. In one embodiment, the diseases are bone-related, such as osteoporosis and osteoarthritis. Subjects' medical images, personal and treatment information are obtained at information collection terminals, for example, at medical and/or dental facilities, and are transferred to a central database, either directly or through a system server. Quantitative information is derived from the medical images, and stored in a central database, associated with subjects' personal and treatment information. Authorized users, such as medical officials and/or pharmaceutical companies, can access the database, either directly or through the central server, to diagnose diseases and perform statistical analysis on the stored data. Decisions can be made regarding marketing of drugs for treating the diseases in question, based on analysis of efficacy, market penetration, and performance of competitive drugs.
To demonstrate the prevalence and risk factors for overactive bladder symptoms associated with artificial urinary sphincter implantation, we investigated the patients who underwent primary artificial urinary sphincter implantation with severe urinary stress incontinence. Forty-eight patients who completely answered the questionnaires of the overactive bladder symptom score before surgery were included. Patient characteristics, urinary status at pre and 1, 3, 6, and 12 months post-device activation, and predictive factors for overactive bladder symptoms were examined. Sixty percent of the patients had preoperative overactive bladder symptoms. Until 12 months after device activation, 35-40% of all patients had overactive bladder symptoms. The rate of persistent and de novo postoperative overactive bladder symptoms was 44.8% and 26.3%, respectively. Daily pad use was not different between patients w/wo overactive bladder symptoms. The only risk factor for postoperative overactive bladder symptoms was a max cystometoric capacity < 200 mL measured by a preoperative urodynamic study. Attention must be given to both persistent and de novo overactive bladder symptoms associated with artificial urinary sphincter implantation for patients with stress incontinence. Counsel should equally be provided for preoperative overactive bladder symptoms, especially in cases with a cystometric capacity < 200 mL.
Static stretching technique was applied to the quadriceps and hamstring muscle groups in both the dominant and non-dominant extremities of the participants in the stretching group. All stretches were performed twice for 20 seconds with a 3-second rest.
The invention relates to a Chinese medicinal composition for relieving drug addition, which is composed of cathartic, vomiting-causing, tonifying and regulating materials. The cathartic materials consist of Rhubarb, Croton Seed (prepared) and Licorice Root. The vomiting-causing materials consist of Muskmelon Base and Licorice Root. The tonifying materials consist of middle-strengthening and qi-benefiting decoction, decoction of eight ingredients, and Spine Date Seed, Chicken Gizzard Skin, Cassia Bark and gardenia. By accurately applying the principle of syndrome-differentiation treatment, the cathartic and vomiting-causing materials can remove toxic materials in human body, the regulating materials can eliminate residual toxins in bowls and stomach, and the tonic materials can invigorate the spleen and stomach and qi and blood. Under the doctor's instruction, the composition can eliminate drug addition completely in days.
Controlled clinical studies have not been conducted in pediatric patients; however, the following suggested dosage table is based on published clinical experience.

Total daily dosage should be divided and equal doses administered orally every 6 hours or at intervals according to individual patient needs. Disopyramide plasma levels and therapeutic response must be monitored closely. Patients should be hospitalized during the initial treatment period, and dose titration should start at the lower end of the ranges provided below.

Since disopyramide phosphate 100 mg capsules contain 100 mg of disopyramide base, the pharmacist can readily prepare a 1 mg/mL to 10 mg/mL liquid suspension by adding the entire contents of disopyramide phosphate capsules to cherry syrup, (Prepare cherry syrup as follows: cherry juice, 475 mL; sucrose 800 g; alcohol, 20 mL; purified water, a sufficient quantity to make 1000 mL). The resulting suspension, when refrigerated, is stable for one month and should be thoroughly shaken before measurement of each dose. The suspension should be dispensed in an amber glass bottle with a child-resistant closure.
The present invention relates to an extract liquid in which the active ingredient of Dendropanax morbifera LEV. is eluted. A Dendropanax morbifera LEV. extract liquid which has enhanced pharmaceutical efficacy and can be easily drunk can be obtained by finely cutting and mixing balsam pear and Dendropanax morbifera LEV., adding water and heating the same, inducing elution of both active ingredients of the balsam pear and the Dendropanax morbifera LEV., and filtering solid parts from the resultant product. According to the present invention, a Dendropanax morbifera LEV. extract liquid in which the active ingredient of Dendropanax morbifera LEV. is sufficiently eluted can be prepared. Accordingly, in addition to a health enhancing effect of the Dendropanax morbifera LEV., specified effects of blood sugar dropping and skin treatment can be obtained by enhancing the extract liquid based on the effect of balsam pear.
The exercise group will participate in home-based hand and foot exercises for 8 weeks. The exercise program will start the week the first neuropathy symptom appears and continue for 8 weeks. The exercises, which will last for 8 weeks, will be performed 3 times a day and at least 3 times a week. A detailed exercise brochure will be given to the exercise group. Patients in the massage ball group will be given a massage ball to be used in exercises.
To provide a hair cleanser composition which can wash hair with a comfortable and smooth foam even to the damaged hair and gives softness and an excellent moisturizing feeling to the hair during rinsing.SOLUTION: There is provided a hair cleanser composition which comprises the following components (A) to (E). The component (A) is an anionic surfactant. The component (B) is an amphoteric surfactant. The component (C) is a cationic polymer. The component (D) is a highly polymerized polyethylene glycol. The component (E) is at least one selected from the group consisting of vegetable oils and fats and vegetable oils and fats derivatives.SELECTED DRAWING: None
OBJECTIVE: To analyze health care treatment experiences among a diverse cohort of reproductive-aged women from the All of Us study, focusing on variations due to body mass index (BMI).
METHODS: We conducted a cross-sectional study that used data from the All of Us Research Program. We analyzed weight bias among reproductive-aged women aged 18-44 years. Weight bias was assessed using a proxy 7-item survey that evaluated discrimination in health care experiences, including courtesy, respect, service quality, being treated as competent, displaying fear, being treated as inferior, and being listened to during health care visits.
RESULTS: Overall, 16,791 reproductive-aged women (mean [SD] age, 35.8 [6.3]) were included in the study. Of 11,592 patients with data available on BMI, 582 were Asian (5.0%), 1,984 (17.1%) were Hispanic or Latinx, 1,007 (8.7%) were non-Hispanic Black, and 7,370 (63.6%) were non-Hispanic White. Approximately 24.2% of participants (n=2,878) had obesity, and 11.1% of participants (n=1,292) had severe obesity. In general, participants in higher BMI categories had negative experiences in the health care setting. Women with severe obesity were 1.5 to 2 times more likely to report poor experiences with their health care clinicians compared with women with healthy weight.
CONCLUSION: Results show significant disparities in the health care experiences among reproductive-aged women. As participants' BMI category increased, so did their negative experiences in the health care setting. These findings underscore the urgent need for targeted interventions to address these inequities. Health care systems must prioritize strategies to ensure that all individuals, regardless of weight or BMI, receive equitable and respectful care.
A cosmetic composition comprising the extract of Halocynthia sp. shell is provided to reduce effectively the amount of melanin pigment produced without cytotoxicity, so that the composition is useful for whitening the skin and face. A cosmetic composition for whitening the skin and face comprises the extract of Halocynthia sp. shell which is prepared by extracting Halocynthia sp. shell with a solvent selected from water, C1-C4 alcohol and a mixed solvent thereof, preferably water with sonication, adding ethyl acetate into the water extract of Halocynthia sp. shell to obtain a water fraction, adding butanol into the water fraction and obtaining the water fraction, and drying the water fraction via freeze-drying process.
Disabled people with a high cervical cord injury or quadriplegia face difficulties when controlling a computer. This study presents a digital mouth-controlled mouse-control aid called the bite-press mouth-controlled mouse (BPMCM) to replace the traditional computer mouse. The BPMCM is equipped with a joystick and micro switch, and the disabled person uses neck and head movements to push the joystick and control the cursor position while the three mouse functions (i.e., left-click, right-click, and drag) are activated by bite-pressing for different time intervals. The proposed design eliminates the sip-and-puff technique and the need to recite orders for reduced adaptation time and increased convenience. Furthermore, this design supports plug-and-play and hot plugging in modern mainstream operating systems that can often be directly operated via mouse functions. Experimental results demonstrated that disabled people using a BPMCM were as capable as healthy participants in operating a computer, with both experiments completed within 5 min, and voluntary disabled people immediately adapted to the BPMCM. The proposed design is expected to allow disabled people to operate computers at the same level as healthy participants. The BPMCM also required only half the physical exertion of other mouth-controlled mouse-control aids that require orders to be recited.
In an embodiment, a method ( 100 ) is described. The method is a computer-implemented method. The method comprises receiving ( 102 ) imaging data of a region comprising a radiographic imaging apparatus couch; and an indication of a specified number, type and position of at least one couch accessory associated with use of the radiographic imaging apparatus couch by a subject. The method further comprises determining ( 104 ) a type and position of at least one target object in the region using an instance segmentation model for processing the imaging data. Determining the type of the at least one target object comprises determining whether or not the at least one target object is a type of couch accessory specified by the indication. The method further comprises comparing ( 106 ) the determined position of the at least one target object that is determined to be the type of couch accessory specified by the indication with the indicated specified position for the couch accessory. The method further comprises, in response to determining that the determined position of the at least one target object does not correspond to the indicated specified position for the couch accessory, indicating ( 108 ) that the couch accessory is incorrectly positioned.
Idiopathic pulmonary fibrosis (IPF) is characterized by progressive fibrosis in the lungs. Activated fibroblasts play a central role in fibrogenesis and express fibroblast activation protein α. A truncated, soluble form (sFAP) can be measured in blood and is a potential novel biomarker of disease activity. The aim was to study the association between sFAP and clinical, radiological, and histopathological measures of disease severity, progression, and survival in a prospective, multicentre, real-world cohort of patients with IPF. Patients with IPF were recruited from the tertiary interstitial lung disease centres in Denmark and followed for up to 3 years. Baseline serum levels of sFAP were measured by ELISA in patients with IPF and compared to healthy controls. Pulmonary function tests, 6-minute walk test and quality of life measures were performed at baseline and during follow-up. The study included 149 patients with IPF. Median sFAP in IPF was 49.6 ng/mL (IQR: 43.1-61.6 ng/mL) and in healthy controls 73.8 ng/mL (IQR: 62.1-92.0 ng/mL). Continuous sFAP was not associated with disease severity, progression or survival (p > 0.05). After dichotomization of sFAP below or above mean sFAP + 2 SD for healthy controls, higher levels of sFAP were associated with lower FVC % predicted during follow-up (p < 0.01). Higher than normal serum levels of sFAP were associated with longitudinal changes in FVC % predicted, but sFAP did not show clear associations with other baseline or longitudinal parameters. As such, sFAP has limited use as a biomarker of disease progression or survival in patients with IPF.
Methods of inducing an immune response against an immunogen in an individual are disclosed. The methods comprise administering to the individual, one or more nucleic acid molecules that comprise a nucleotide sequence that encodes an immunogen and a nucleotide sequence that encodes a Major Histocompatibility Complex antigen. The nucleotide sequences that encode the immunogen and Major Histocompatibility Complex antigen are expressed when taken up by cells of the individual and an immune response against the immunogen is induced in the individual. Methods of reducing rejection of unmatched donor cells, tissue or organ in an individual undergoing cell, tissue or organ transplantation are disclosed. The methods comprise administering to the individual, one or more nucleic acid molecules that comprise a nucleotide sequence that encodes a death signal or toxin and a nucleotide sequence that encodes a major Histocompatibility Complex antigen that is matched to the donor cells, tissue or organ. The nucleotide sequences that encode the Major Histocompatibility Complex antigen and death signal or toxin are expressed when taken up by cells of the individual. T cell death through interaction with the death signal or toxin results in a reduction of rejection of unmatched donor cells, tissue or organ. Methods of reducing a dominant immune response in an individual and methods of expanding a subpopulation of T cells associated with a specific immune response are also described. Plasmids and compositions comprising plasmids useful for practising the method are described.
This clinical study, "BCMA nano-antibody CAR-T cells in the treatment of refractory recurrent multiple myeloma clinical research," is a single center, single arm, open design. The aim is to study the safety and efficacy of BCMA nano antibody CAR-T in the treatment of MM. In this study, a 3 + 3 dose gradient climbing design was used. Three dosage groups, 5x106 / kg, 1x107 / kg and 1.5x107 / kg, were divided into three groups.
Decoding death and dying in people with dementia by digital thanotyping (5-D) aims to pioneer the methodology of defining perceived dying by a data- and knowledge-driven digital representation of the end-of-life trajectory and its associated processes inferred from different measurements. The investigator proposes a novel digital thanotyping approach (Greek for thánatos) defined as the moment-by-moment in-situ quantification of the individual state of the human body. In 5-D, the investigator defines the "point of no return" as the declining state from which the person with dementia does not recover and marks the beginning of the perceived dying. In this trial the investigator describes methods and tools to define dying to an unprecedented level of accuracy and robustness, within a timespan larger than is possible now in one of the most difficult to access and vulnerable groups. Results will be transferable to other life-threatening diseases, relevant for hospitals and homecare services alike. The investigator hypothesizes that, from monitoring the evolution of clinical manifestations over time and their interdependencies, the prediction of the point of no return is possible.

5-D is a 5-year, multicenter, observation-analytic, longitudinal study aimed toward method development combining clinical data and information with systems modelling and systems identification. The investigator will recruit people with dementia (N=480) from the 10-12 Norwegian nursing homes (NH) from the Bergen Municipality, which have a cumulative capacity of \>800 patients/year (out of a total of 2500 patients/year across the municipality). The recruitment pool will be extended, if necessary, to other NHs within the municipality. The investigator chooses NHs as the location for this research (instead of patient homes) because 57% of the dying population and 97% of all people with dementia in Norway die in NHs.(12) Most people in NHs present multimorbidity; among them, 52% have severe dementia (Mini-Mental-State Examination, MMSE score 0-11), 25% moderate dementia (MMSE 12-17), 16% mild dementia (18-23), and 6% no dementia (24-30).(13) Inclusion criteria: NH inhabitants \>64 years, with significant cognitive impairment.(14) Exclusion criteria: people without informed/presumed consent, people already participating in other studies, people who might be distressed by sensors.
The present invention is based on the finding that through modulation of the function, activity and/or expression of the liver X receptor (LXR) α and/or the peroxisome proliferator- activated receptors (PPAR) α proteins (and/or genes encoding the same), it is possible to modulate cholesterol efflux from macrophages. PPARα is a nuclear receptor protein which functions as a transcription factor to regulate the expression of genes. The PPARα isoform is encoded by the  PPARα  gene located at 22q12-13.1 on the human chromosome. LXR is a member of the nuclear receptor family of transcription factors. The LXRs are important regulators of cholesterol, fatty acid, and glucose homeostasis. The LXRα isoform is encoded by the  LXR α gene located at 11p11.2 on the human chromosome.
A fluid replacement device and method. A console includes a weighing subsystem responsive to a first fluid source and a urine collection chamber. A pump is configured to infuse fluid from the first fluid source into a patient. A processing subsystem in the console is responsive to the weighing subsystem. Based on the weight of the first fluid source and the weight of the urine collection chamber, the patient's urine output and the amount of fluid infused into the patient from the first fluid source are determined. A user interface in the console allows the user to set a desired fluid balance for the patient and the amount of at least one additional fluid delivered to the patient. An actual fluid balance is calculated based on the determined urine output, the determined amount of fluid infused into the patient from the first fluid source, and the set amount of the at least one additional fluid delivered to the patient. The pump is controlled based on the actual fluid balance and the set desired fluid balance so the actual fluid balance becomes the same as or approximately the same as the desired fluid balance.